A case report of de novo hepatocellular carcinoma after living donor liver transplantation
详细信息 查看全文
- 作者：Songfeng Yu (1) (2) (3)
Hua Guo (1) (2) (3)
Li Zhuang (1) (2) (3)
Jun Yu (1) (2) (3)
Sheng Yan (1) (2) (3)
Min Zhang (1) (2) (3)
Weilin Wang (1) (2) (3)
Shusen Zheng (1) (2) (3) - 关键词：De novo hepatocellular carcinoma ; Liver transplantation ; Living donor liver transplantation ; Hepatitis B recurrence ; YMDD mutation
- 刊名：World Journal of Surgical Oncology
- 出版年：2013
- 出版时间：December 2013
- 年：2013
- 卷：11
- 期：1
- 全文大小：637KB
- 参考文献：1. Herrero JI: De novo malignancies following liver transplantation: impact and recommendations. / Liver Transpl 2009,15(Suppl 2):S90-S94. CrossRef
2. Yao FY: Liver transplantation for hepatocellular carcinoma: beyond the Milan criteria. / Am J Transplant 2008, 8:1982鈥?989. CrossRef
3. Torbenson M, Grover D, Boitnott J, Klein A, Molmenti E: De novo hepatocellular carcinoma in a liver allograft associated with recurrent hepatitis B. / Transplant Proc 2005, 37:2205鈥?206. CrossRef
4. Saxena R, Ye MQ, Emre S, Klion F, Nalesnik MA, Thung SN: De novo hepatocellular carcinoma in a hepatic allograft with recurrent hepatitis C cirrhosis. / Liver Transpl Surg 1999, 5:81鈥?2. CrossRef
5. Levitsky J, Faust TW, Cohen SM, Te HS: Group G streptococcal bacteremia and de novo hepatocellular carcinoma after liver transplantation. / Liver Transpl 2002, 8:572. CrossRef
6. Croitoru A, Schiano TD, Schwartz M, Roayaie S, Xu R, Suriawinata A, Fiel MI: De novo hepatocellular carcinoma occurring in a transplanted liver: case report and review of the literature. / Dig Dis Sci 2006, 51:1780鈥?782. CrossRef
7. Flemming P, Tillmann HL, Barg-Hock H, Kleeberger W, Manns MP, Klempnauer J, Kreipe HH: Donor origin of de novo hepatocellular carcinoma in hepatic allografts. / Transplantation 2003, 76:871鈥?73. CrossRef
8. Kita Y, Klintmalm G, Kobayashi S, Yanaga K: Retransplantation for de novo hepatocellular carcinoma in a liver allograft with recurrent hepatitis B cirrhosis 14 years after primary liver transplantation. / Dig Dis Sci 2007, 52:3392鈥?393. CrossRef
9. Sotiropoulos GC, Frilling A, Molmenti EP, Brokalaki EI, Beckebaum S, Omar OS, Broelsch CE, Malag贸 M: De novo hepatocellular carcinoma in recurrent liver cirrhosis after liver transplantation for benign hepatic disease: is a deceased donor re-transplantation justified? / Transplantation 2006, 82:1112. CrossRef
10. Vernadakis S, Poetsch M, Weber F, Treckmann J, Mathe Z, Baba HA, Paul A, Kaiser GM: Donor origin de novo HCC in a noncirrhotic liver allograft 3 years after liver transplantation. / Transpl Int 2010, 23:341鈥?43. CrossRef
11. Morita K, Taketomi A, Soejima Y, Ikegami T, Fukuhara T, Iguchi T, Nagata S, Sugimachi K, Gion T, Shirabe K, Maehara Y: De novo hepatocellular carcinoma in a liver graft with sustained hepatitis C virus clearance after living donor liver transplantation. / Liver Transpl 2009, 15:1412鈥?416. CrossRef
12. Zheng S, Chen Y, Liang T, Lu A, Wang W, Shen Y, Zhang M: Prevention of hepatitis B recurrence after liver transplantation using lamivudine or lamivudine combined with hepatitis B Immunoglobulin prophylaxis. / Liver Transpl 2006, 12:253鈥?58. CrossRef
13. Fung JJ, Jain A, Kwak EJ, Kusne S, Dvorchik I, Eghtesad B: De novo malignancies after liver transplantation: a major cause of late death. / Liver Transpl 2001, 7:S109-S118. CrossRef
14. Dantal J, Soulillou JP: Immunosuppressive drugs and the risk of cancer after organ transplantation. / N Engl J Med 2005, 352:1371鈥?373. CrossRef
15. Penn I: Posttransplant malignancies. / Transplant Proc 1999, 31:1260鈥?262. CrossRef
16. Park HW, Hwang S, Ahn CS, Kim KH, Moon DB, Ha TY, Song GW, Jung DH, Park GC, Namgoong JM, Yoon SY, Park CS, Park YH, Lee HJ, Lee SG: De novo malignancies after liver transplantation: incidence comparison with the Korean cancer registry. / Transplant Proc 2012, 44:802鈥?05. CrossRef
17. Shimizu T, Hayashi M, Inoue Y, Komeda K, Asakuma M, Hirokawa F, Miyamoto Y, Tanigawa N, Uchiyama K: A case of gastric cancer after living donor liver transplantation. / Ann Transplant 2012, 17:122鈥?26.
18. Nissen NN, Martin P: Hepatocellular carcinoma: the high-risk patient. / J Clin Gastroenterol 2002, 35:S79-S85. CrossRef
19. Faria LC, Gigou M, Roque-Afonso AM, Sebagh M, Roche B, Fallot G, Ferrari TC, Guettier C, Dussaix E, Castaing D, Brechot C, Samuel D: Hepatocellular carcinoma is associated with an increased risk of hepatitis B virus recurrence after liver transplantation. / Gastroenterology 2008, 134:1890鈥?899. quiz 2155 CrossRef
20. Bartholomeusz A, Locarnini SA: Antiviral drug resistance: clinical consequences and molecular aspects. / Semin Liver Dis 2006, 26:162鈥?70. CrossRef
21. van der Eijk AA, Hansen BE, Niesters HG, Janssen HL, van de Ende M, Schalm SW, de Man RA: Viral dynamics during tenofovir therapy in patients infected with lamivudine-resistant hepatitis B virus mutants. / J Viral Hepat 2005, 12:364鈥?72. CrossRef
22. Sheng YJ, Liu JY, Tong SW, Hu HD, Zhang DZ, Hu P, Ren H: Lamivudine plus adefovir combination therapy versus entecavir monotherapy for lamivudine-resistant chronic hepatitis B: a systematic review and meta-analysis. / Virol J 2011, 8:393. CrossRef
23. Mas VR, Maluf DG, Dumur CI, Archer KJ, Yanek K, Jackson-Cook C, Fisher RA: Molecular techniques for identifying HCC origin and biology after orthotopic liver transplantation. / Diagn Mol Pathol 2006, 15:90鈥?4. CrossRef
24. Hosaka T, Suzuki F, Kobayashi M, Hirakawa M, Kawamura Y, Yastuji H, Sezaki H, Akuta N, Suzuki Y, Saitoh S, Arase Y, Ikeda K, Miyakawa Y, Kumada H: Development of HCC in patients receiving adefovir dipivoxil for lamivudine-resistant hepatitis B virus mutants. / Hepatol Res 2010, 40:145鈥?52. CrossRef - 作者单位：Songfeng Yu (1) (2) (3)
Hua Guo (1) (2) (3)
Li Zhuang (1) (2) (3)
Jun Yu (1) (2) (3)
Sheng Yan (1) (2) (3)
Min Zhang (1) (2) (3)
Weilin Wang (1) (2) (3)
Shusen Zheng (1) (2) (3)
1. Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, 310003, China
2. Key Laboratory of Combined Multi-Organ Transplantation, Ministry of Public Health, First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, 310003, China
3. Key Laboratory of Organ Transplantation, Zhejiang Province, Hangzhou, 310003, China
文摘
Post-transplant malignancy is the major cause of later death of recipients after liver transplantation. Tumor recurrence after liver transplantation for patients with hepatocellular carcinoma in the end stage of cirrhosis has been frequently encountered. However, de novo hepatocellular carcinoma originating from the liver allograft has only rarely been reported. Here we reported a case of de novo hepatocellular carcinoma developed 2 years after living donor liver transplantation for hepatitis B-related liver cirrhosis with viral YMDD mutation. To the best of our knowledge, this is the first report of de novo hepatocellular carcinoma in a liver graft with recurrent hepatitis B virus infection after liver transplantation for hepatitis B-related liver cirrhosis with YMDD mutation. Moreover, the de novo cancer first presented as a lung mass with minimal liver involvement and was obscured by a pulmonary fungal infection.